Literature DB >> 16696337

A study on the traditional Chinese medicine Jinyebaidu for prevention and treatment of intrauterine infection with guinea pigs cytomegalovirus.

Suhua Chen1, Jinwen Xiong, Wei Xing, Liangzhen Wen, Haizhi Liu, Xinrong Wang.   

Abstract

The purpose is to study the prophylactic and therapeutic effect of the traditional Chinese Medicine (TCM)-Jinyebaidu (JYBD) to guinea pig cytomegalovirus (GPCMV) intrauterine infection. The virus-free female and male guinea pigs were screened with nest-polymerase chain reaction (N-PCR). After inbred, pregnant guinea pigs were selected and divided into 3 groups randomly: 5 guniea pigs of the blank control group were not given either GPCMV or JYBD. 31 guniea pigs of the positive control group were inoculated 1 mL (10(7) TCID50) suspension of GPCMV intraperitoneal. 10 guniea pigs of the experimental group were inoculated GPCMV firstly and then perfused stomach with JYBD for 14 days (Dosage in accordance with the modulus of the weight ratio of human to guniea pig). The effects of JYBD on the intrauterine infection of GPCMV were observed. The results showed that JYBD could decrease the maternal infection rate from 100% (31/31) to 50% (5/10) (P < 0.001), the intrauterine infection rate from 100% (72/72) to 75% (21/28) (P < 0.001), and the rate of abnormal outcome of pregnancy from 64.4% (29/45) to 25.0% (7/28) (P < 0.001), the infective symptoms being relieved. It can be concluded that traditional Chinese medicine- JYBD can prevent and treat (GPCMV intrauterine infection, and can be expected a prophylactic drug for HCMV intrauterine infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16696337     DOI: 10.1007/bf02896182

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  6 in total

1.  Experimental congenital infection with cytomegalovirus: a guinea pig model.

Authors:  M L Kumar; G A Nankervis
Journal:  J Infect Dis       Date:  1978-11       Impact factor: 5.226

2.  [Clinical and experimental study on antiviral activity of reduqing against human cytomegalovirus].

Authors:  W Xing; L Wen; J Dong
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  2000-04

3.  Reduced congenital cytomegalovirus (CMV) infection after maternal immunization with a guinea pig CMV glycoprotein before gestational primary CMV infection in the guinea pig model.

Authors:  C J Harrison; W J Britt; N M Chapman; J Mullican; S Tracy
Journal:  J Infect Dis       Date:  1995-11       Impact factor: 5.226

4.  Cytomegalovirus infection in guinea pigs. IV. Maternal infection at different stages of gestation.

Authors:  B P Griffith; G D Hsiung
Journal:  J Infect Dis       Date:  1980-06       Impact factor: 5.226

5.  Cytomegaloviral infections in the guinea pig: experimental models for human disease.

Authors:  F J Bia; B P Griffith; C K Fong; G D Hsiung
Journal:  Rev Infect Dis       Date:  1983 Mar-Apr

6.  Effect of passive antibody on congenital cytomegalovirus infection in guinea pigs.

Authors:  D F Bratcher; N Bourne; F J Bravo; M R Schleiss; M Slaoui; M G Myers; D I Bernstein
Journal:  J Infect Dis       Date:  1995-10       Impact factor: 5.226

  6 in total
  3 in total

1.  Anti-viral effects of urosolic acid on guinea pig cytomegalovirus in vitro.

Authors:  Jingjing Zhao; Juanjuan Chen; Tao Liu; Jianguo Fang; Jin Wan; Jianhua Zhao; Wei Li; Jing Liu; Xianzhe Zhao; Suhua Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-12-28

2.  The effects of murine cytomegalovirus on the maturation, fertilization, cleavage and blastula formation of mouse oocytes in vitro.

Authors:  Xinrong Wang; Xinhong Zhang; Suhua Chen; Guijin Zhu; Jihui Ai
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-08

Review 3.  Characteristics of registered clinical trials on traditional Chinese medicine for coronavirus disease 2019 (COVID-19): A scoping review.

Authors:  Hui Luo; Ming Yang; Qiao-Ling Tang; Xiao-Yang Hu; Merlin L Willcox; Jian-Ping Liu
Journal:  Eur J Integr Med       Date:  2020-11-12       Impact factor: 1.314

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.